|
|
Article: GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer Vaccines.
- Article from:
- PR Newswire Europe
- Article date:
- January 18, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA, Pennsylvania, January 18 /PRNewswire/ --
- Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX(R), to Merck's Gardasil(R)
GlaxoSmithKline (NYSE: GSK) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R), versus Gardasil(R). The primary objective of the head-to-head trial is to compare the immune responses to HPV types 16 and 18 in U.S. women 18 to 26-years-old. Secondary objectives include evaluating the immune responses to HPV 16 and 18 in women 27 to 35-years-old and 36 to 45-years-old. In addition, the ...